NASDAQ · Biotechnology · USD

Silexion Therapeutics Corp (SLXN) Stock Analysis

Silexion Therapeutics Corp (SLXN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SLXN

$0.35

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SLXN with… →

SLXN Key Statistics

As of Sep 4, 2026

Trading

Open: $0.37
Previous Close: $0.35
Day's Range: 0.35–0.38
52-Week Range: 0.35–77.70
Volume: 202.90K
Beta: −0.36

Valuation

Market Cap: $1.96M
P/E Ratio: unprofitable
EPS (ttm): −19.91

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$11.91M
Profit margin: 0.00%
Shares Outstanding: 5.56M
1-Year Return: −99.50%

Dividend and dates

Avg Volume: 288.00K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SLXN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−3.20%+4.03%+7.75%−81.47%−93.63%−98.17%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−98.17%
2025	−93.63%
2024	−81.47%
2023	+7.75%
2022	+4.03%
2021 (partial year)	−3.20%

As of September 4, 2026.

SLXN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$11.91M	—
2024	$0.00	−$16.44M	—
2023	$0.00	−$4.94M	—
2022	$0.00	−$3.22M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$11.63M	−$11.91M	—
2024	$0.00	—	−$12.57M	−$16.44M	—
2023	$0.00	—	−$4.68M	−$4.94M	—
2022	$0.00	—	−$3.86M	−$3.22M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SLXN Valuation vs Biotechnology Median

Median of 656 stocks

Metric	SLXN	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Silexion Therapeutics Corp (SLXN) is capitalised at $1.96M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 13 employees.

SLXN last closed at $0.35 on September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $0.35 to $77.70. The latest close sits 0.57% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $11.91M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −19.91.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at −0.36. Daily returns over the trailing 5 years annualize to a volatility of 419.27%. The trailing one-year price return is −99.50%. Across 5 years the annualized return works out at −81.07%.

Growth & Income

No dividend is on file for SLXN.

2026 is still running; the price is −98.17% year to date. Across the complete calendar years on file, 2023 returned +7.75% and 2025 returned −93.63%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Silexion Therapeutics Corp (SLXN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Silexion Therapeutics Corp	SLXN	$1.96M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Silexion Therapeutics Corp has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Silexion Therapeutics Corp

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Visit website →